TG Therapeutics poised to advance next week, says Roth Capital Roth Capital expects TG Therapeutics' A. Phase II combination data from the TG-1101 / Imbruvica study in B-cell malignancies. expected to be presented this weekend, to be strong. The firm expects the stock to rise at the beginning of next week, and it reiterates a Buy rating on the shares. The firm continues to identify the stock as a Focus Pick.